perfect precis product address frontier target initi buy pt
gener ipo februari histor financi data
cut edg precis medicin oncolog
initi coverag next-gener cancer-
focus biotech compani focus frontier targetskey signal
transduct protein either avail direct
inhibitor agent directli inhibit target work
mechan action may suppress full rang way
downstream signal drive cancer compani primarili
aim ra mtor pathway two fundament signal
network implic rang aggress hitherto
intract tumor type revolut advanc array potent
select highli specif tractabl small molecul candid
advanc compound inhibitor
phase program evalu monotherapi plu
valid partnership major pharmaceut firm
compani ink marque partnership lead asset sanofi
top multi-national pharma extens track record
success drug develop cancer well-known chemo
drug taxoter docetaxel eloxatin oxaliplatin well
target therapi caprelsa vandetanib jevtana cabazitaxel
checkpoint inhibitor libtayo cemiplimab sanofi deal
carri attract term view up-front payment june
total futur mileston payment profit
split includ co-promot option coverag
 cost
encourag efficaci data thu far much come
expect addit data phase trial evalu
monotherapi phase trial test combin cotel
later year phase studi report initi efficaci kra
mutant non-smal cell lung cancer nsclc patient
confirm object respons rate orr confirm orr
kra mutant mutant respect intermitt
dose achiev safeti toler maintain appropri
pharmacokinet pk profil plasma concentr
level preclin evid point impress synergi mutant
kras-target drug bode well plu
combo multipl pair inhibitor also involv
data phase monotherapi studi potenti initi efficaci
data initi safeti data alreadi proven favor phase
combo trial cotel
pandem impact appear unlik given late-stag aggress
intract natur patient popul target
colorect cancer feel unlik revolut sanofi
would experi signific impact clinic develop due
pandemic-rel restrict patient
exhaust option
definit distribut analyst rate analyst certif disclosur pleas refer page report
preclin evid appear support wide array front acknowledg may
appear early-stag feel substanti bodi data contextu reinforc compani drug develop
effort firstli protein tyrosin phosphatas ptp enzymei consid central node ra pathway
drive aggress growth multipl cancer type signal multipl receptor tyrosin kinas rtk thu
inhibit deploy strategi build combinatori regimen involv pair kinas inhibitor
block target like egfr metal valid alreadi form basi multipl approv
drugs tagrisso osimertinib xalkori crizotinib cotel cobimetinib feel like effect
pair drug like next-gener compound tagrisso permit defeat one
elus difficult resist mechan cancerso-cal paradox reactiv wherein tumor cell lose
neg feedback loop typic act brake uncontrol ra pathway signal downstream target
ra pathway mitogen-activ protein kinas mapk block use tradit rtk inhibitor view
preclin evid multipl anim model includ highli aggress xenograft vitro studi detail later
report demonstr addit inhibitor like kinas inhibitor like tagrisso
cotel comprehens address paradox reactiv broad implic treatment hitherto-intract
cancer like kra mutant nsclc well late-stag pancreat cancer
substanti high-valu market beckon within precis oncolog would point five key item investor within
context precis oncolog see highli relev revolut commerci futur signific percentag
tumor exhibit ras-mut statu includ nearli lung colorect adenocarcinoma roughli
pancreat adenocarcinoma indic may blockbust opportun even within seemingli narrow nich
mani mutat driver malign mean cancer question reliant upon
exist therapeut even exhibit activ resistance-conf mutat within ra pathway
deal consequ paradox reactivationrend partial effect downright toothless
multipl target therapi precis medicin aim solid tumor could product pair inhibitor
like mention creat network opportun revolut benefit deploy
combinatori regimen recent year precis oncolog becom decidedli hot ticket within cancer arena
multipl compani focu either high-profil initi public offer ipo like black diamond
current market cap springwork inde lucr transact
notabl acquisit loxo oncolog co earli purchas array biopharma
project revolut could achiev peak sale nearli
ra inhibitor view alon could achiev peak sale believ
could launch earli ra inhibitor follow follow februari ipo revolut
end cash equivalentsw believ suffici fund oper well
given nich natur precis oncolog feel revolut could pursu forward integr establish
commerci infrastructurewith sanofi helparound also note kind drug typic command
high price monthli rang per patient
valuat risk assess revolut medicin use discount cash flow dcf -base methodolog ascrib
valuat ra inhibitor without contribut element compani pipelin
employ probabl launch regimen compris either inhibitor ra
inhibitor alon nsclc probabl launch egfr-posit nsclc probabl
launch mek inhibitor variou mutant nsclc case pair checkpoint
inhibitor nsclc believ natur target fulli appreci street
furthermor compet compani target oncolog arena focu kinas rather phosphatas target
vantag point allow revolut differenti exploit function central node
kinas signal cascad process addit util discount rate termin growth rate along
effect tax rate risk includ limit clinic setback inabl secur
regulatori approv time fashion poorer-than-anticip commerci perform within
variou combinatori set due greater-than-project competit pressur price issu macroeconom factor
failur pipelin candid notabl ra inhibitor possibl impact pandem
may make clinic trial execut challeng imposs
tabl content
sanofi partnership provid clinic develop experi commerci muscl
revolut kra inhibitor could improv upon efficaci
revolut inhibitor round pipelin present upsid valuat
major pharma appetit precis oncolog asset compani clear
review outlook
histor incom statement financi project
histor balanc sheet financi project
statement financi project
found
headquart redwood citi ca
employe
revolut medicin next-gener clinical-
target therapi inhibit elus frontier target
within well-known growth surviv pathway
princip emphasi ra mtor signal
pathwayslead asset potent
select inhibitor central node
ra pathway
multipl addit pipelin asset constitut
potent select cell-act inhibitor ra activ
formref ra
februari initi public offer ipo
per share rais million gross proce
share trade
sinc ipo share appreci
xbi spdr biotech index
time frame
cash million
follow
complet ipo provid
oper runway well
multi-cohort phase clinic
program span test monotherapi
combin cotel cobimetinib approv
mek inhibitor market genentech
subject partnership sanofi
combin mek
egfr kra inhibitor plu synergi
therapeut class current high demand
pharmaceut firm novarti
million mileston payment
million development-rel
profit split co-promot option
revolut sanofi pay cost
public firm mention compris follow sanofi sni rate
agentcatalysttimingimpactthre preclin present intermitt dose schedul trial tagrisso trial trial updat combin inhibitornomin first develop preclin poster phase data /- kisqali phase revolut medicin inc
could constitut backbon multipl regimen
mediat signal transduct variou receptor tyrosin kinas
rtk egfr meta core compon
signal multi-protein complex downstream activ
rtk believ mechanist rational target
rtk-driven tumor sound belief
reinforc preclin evid show enhanc efficaci
inhibitor plu rtk inhibitor rtk-driven tumor
discuss notabl address egfr
mutat occur roughli nsclc patient
addit play key role rtk signal transduct
shown play central indispens role
improv efficaci
demonstr potenti
combin inhibitor kras-target agent
tumor ad
evid initi clinic data demonstr modest preliminari
sign clinic activ monotherapi
select kras-mut
also key mediat b- t-
may also augment efficaci
 wainwright co modifi corpor present
preclin data support target egfr-mut cancer
addit tagrisso osimertinib
xenograft model display enhanc tumor kill
longer durat effect dose stop
despit impress efficaci tagrisso see page
page clear-cut therapeut option
chemotherapi develop resist one
common resist mechan
amplif occur patient
progress tagrisso seen bottom left
addit tagrisso tagrisso-
control compar tagrisso monotherapi make
sens us sinc receptor also util
signal transduct would also expect see
patient develop amplif
occur tagrisso-tr patient
assum equival efficaci egfr-mut met-
amplifi nsclc believ addit
inhibitor would prefer select tki
 capmatinib inhibitor also
improv tagrisso efficaci absenc resist
mutat amplif occur
may also enhanc efficaci tagrisso
preclin data bridgebio inhibitor
show ad tagrisso
increment suppress tumor cell prolifer ex vivo
mutationth best describ on-target tagrisso
resist mutat detect roughli
patient first-lin tagrisso resist accordingli
benefit deriv ad tagrisso may
extend on-target tagrisso resist mutat well
bridgebio leonetti et al british journal cancer
tagrisso efficaci benchmark egfr nsclc
phase flaura trial tagrisso demonstr
orr cr mdor
month mpf mo believ rmc-
tagrisso would demonstr
approxim increas mpf mo
order establish standard-of-car
regimen egfr nsclc patient
congruent observ egfr nsclc ad
inhibitor could also show increment efficaci benefit alk nsclc
standard-of-car nsclc up-front
inhibitor egfr nsclc develop
resist mechan bound occur notabl
patient treat later-gener inhibitor
develop higher percentag off-target resist
mechan seen addit
inhibitor case zykadia ceritinib
demonstr reduc level palk perk well
enhanc anti-tumor activ compar either
agent alon patient progress
histor project egfr inhibitor sale
sinc fda approv tagrisso osimertinib front-lin
egfr nsclc patient base posit phase
flaura trial result tagrisso becom standard-of-
care front-lin agent patient current garner
major new prescript within egfr-target
class agent
consid project sale tagrisso
billion top left see signific commerci potenti
opportun egfr nsclc furthermor
although includ sale contribut
may
meaning potenti upsid rtk-driven cancer
 project sale inhibitor
potenti indic
categorymutationkey cancer typesegfr ret cancerkra nsclcbrafmelanomakra amplificationesophag gastric lofmelanoma nsclc ovarian bladder treat tumors-nsclc melanoma rcc uc scchn etcrtk genet alter fusionsconstitut activ ras/mapk signal revolut medicin inc
move mapk pathway delet result prolong
surviv tumor preclin model
pancreas-specif biallel delet
mice term kra result
complet blockag pancreat
surviv dramat prolong
delet
even rapid context
loss result substanti
deceler non-smal cell
nsclc diseas dynam reduc tumor
burden translat consider
howev kra mutat depend drive signal
sensit inhibit
sensit inhibit
although one would assum play role drive
downstream signal promot cycl ras-gdp
inact ra ras-gtp activ ra kra mutant
sinc sit ra mapk pathway ahm
colleagu show treatment
hour certain kra mutant
appear suppress erk phosphoryl meaning
degre implic
mutat reliant mediat downstream
signal would expect inhibit
demonstr effect anti-tumor activ
furthermor even within mutant variant
see variabl degre inhibit
reduc level ras-gtp shown top
fibroblast transduc differ kra mutat
addit inhibitor
tool compoundreduc level ras-gtp
mutant contrast see
reduct ras-gtp mutant
sensit vari across cell line
anoth factor consid intrins
variabl depend cell
line
kras-
depend deriv project drive reveal
signific correl kras-depend
sensit within
relationship appar kra mutat
outsid
depend kra signal drive tumor growth
vari cell line exhibit lower
consist preclin data monotherapi display initi
clinic efficaci mutat nsclc tumor
growth dose-depend manner patient-
notabl intermitt dose mg/kg
display deeper frequent anti-tumor
activ mg/kg qd dose nsclc nci-
efficacy-evalu mutant nsclc patient
phase
demonstr confirm orr
confirm orr mutant nsclc patient
find initi efficaci encourag note
could
improv dose-escal intermitt schedul
continu cohort mg/kg believ
modest probabl would illicit similar respons
rate seen orr
directli inhibit driver mutat
combinatori regimen view
initi monotherapi efficaci bode well
rel level expand peak-to-trough ratio
feel intermitt dose schedul enabl establish manag optim safeti toler
profil fact plasma concentr breach level remain suffici time facilit appropri
target inhibit impli efficaci compromis constitut posit achiev best world
allow higher dose result potenti greater anti-
preclin data also point enhanc efficaci combin
reactiv
seen slide inhibit part mapk
pathway reduc level perk
result
loss neg feedback loop typic inhibit
rtk raf activ consequ see
mapk pathway
stand reason vertic inhibit two
point within cascad could potenti
residu signal improv efficaci exampl
combin braf inhibitor plu mek
inhibitor demonstr improv efficaci compar
either agent alon mutat cancer
ryan colleagu demonstr administr
result paradox
reactiv mapk pathwaydriven loss
neg feedback loop rtk result
enhanc activ wild-typ kra
show combin
inhibit
shp rmc
led
enhanc suppress mapk pathway time
model top left well reduc tumor cellular
author
preclin data also point enhanc efficaci combin
addit reduc level activ
ra compar either agent alon preclin model
consequ phosphoryl erk meaning impair
perk activ form erk downstream effector
top right
combin two administ daili mice bear
cell
combin treatment led statist signific reduct
tumor growth compar either agent alon assess
last day dose demonstr slower rate tumor rebound
post treatment withdraw notabl inhibit synerg
kra target agent high across variou mutat
mutat kra amplif braf class mutat lof mutat
inhibit one part
mapk pathway result paradox reactiv see
accordingli preclin data suggest rmc-
ad mek inhibitor cobimetinib could
improv anti-tumor activ compar either agent
alon dose lower monotherapi dose
reactiv
competit landscap perspect point
inhibitor trametinib mek inhibitor erk
inhibitor novarti
inhibitor boehring ingelheim
inhibitor springwork beigen
although similar combin face toler issu initi safeti
pk data cobimetinib encourag view
advanc
kras-mut nsclc pancreat cancer
studi dacomitinib initi dose
maximum toler doseand mirdametinib
administ
recommend
monotherapi dose eventu howev intermitt
dose schedul implement due poor toler
albeit higher dose mirdametinib
allow plasma concentr mek inhibitor
exceed target inhibit level despit intermitt
schedul dose achiev target inhibit
regimen
recommend combo explor
revolut phase trial current
examin combin twice-weekli
daili cotel cobimetinib day
second dose schedul slate examin
dose cobimetinib intermitt
initi dose level appear tolerablealthough may
chang dose-escal continuesand steadi
state plasma concentr
see figur left overal
believ initi safeti pk data encourag
shall monitor safeti profil close move forward
one hand inhibit alloster
inhibit revers inhibitori effect cell trigger
cancer
normal antitumor immun green
inhibit also contribut cell activ
call enhanc anti-tumor immun
red normal enhanc anti-
tumor immun inhibit play role anti-
tumor effect inhibit vivo
shown syngen model
typic exhibit immun exclud
phenotypeth combin
display greater anti-tumor activ
either agent alon
revolut medicin et al intern journal molecular scienc
particularli relev therapi appear
efficaci kras-mut cancer
one outstand question involv kras-target
agent might util physician age
immunotherapi advent immunotherapi
revolution treatment paradigm signific
portion individu afflict cancer efficaci
approach vari greatli across differ immun
molecular profil tumor
immunotherapi appear
howev note
kras-mut
nsclc recent present result
trial present
esmo io late reinforc notion
although respons rate keytruda monotherapi
kra nsclc appear similar seen
mutant-select kra
agent may still deliv superior mpf and/or mo
kras-target agent like pair anti-pd-
agent view
combin agent
overal
surviv monotherapi either agent preclin
npf ci os ci npf ci os chemo avastin vs vs vs vs chemo vs vs keytruda tecentriq vs docetaxeltecentriq vs docetaxeltrialag revolut medicin inc
pharmacokinet comparison
unknown current administ
dose schedul monotherapi dose-
escal recommend phase dose
shall note appear demonstr
higher cmax auc compar
given
dose mice similar pattern
emerg one assum show compar
pk properti
cynomolgu monkey
human necessarili mean howev
shall demonstr superior efficaci
sinc could result increas toxic
thu lead lower select
pk data
single-dos pk data
non-risk-adjust global sale revolut medicin forecast
forecast
nsclc
combin
cobimetinib keytruda
chemo assum market
entri combin could occur
respect potenti entri
occur one year approv
indic
penetr rmc-
tagrisso combo
cobimetinib
probabl approv
respect
treatment cost
per month in-
line
sanofi partnership provid clinic develop
experi commerci muscl
commerci agreement aventi inc affili
sanofi research develop inhibitor includ rmc-
indic agreement assign
up-front juli could also receiv million
develop regulatori commerci mileston payment
sanofi agreement revolut
research
respons perform preclin
inhibitor sanofi agre reimburs revolut
intern extern research cost expens incur
research plan
intern extern cost
program sanofi
genzym shall lead clinic develop revolut elig
receiv profit loss
high single-digit mid-teen percentag royalti annual
net sale outsid
overal view revolut partnership sanofi rmc-
favor believ sanofi
burgeon forc
oncolog sever oncolog asset clinic develop see
tabl left larg experienc sale forc
revolut kra inhibitor could improv upon
efficaci
approxim human cancer attempt
directli inhibit select ra isotyp stifl
long time howev recent advanc ra
target made possibl directli target mutant
ra mirati
target kra
state singl kra mutat
could
advanc ra
addit possibl expand pool patient
may benefit
kras-target agent
preclin data point potenti enhanc efficaci
profil rel kra target agent
signific percentag tumor ras-mut
initi respons rate target agent seem encourag
respons rate seen
nsclc appear rel
compar keytruda monotherapi
keytruda chemo demonstr
orr respect nsclc
patient keynote-
appear gener respons
rate patient support
idea pair kras-target agent
therapi juri still
monotherapi agent opinion
traediscont due full dose-escal dose-expans popul three trae seenamg revolut medicin inc
howev resist mechan bound develop
reactiv
resist previous
one mechan
discuss paradox
mapk
pathwaydriven loss neg feedback loop
occur administr inhibitor
result enhanc activ wild-
type kraswhich inhibit kras-mut
specif inhibitor state earlier could potenti
address combin inhibitor kras-
addit loss neg feedback loop lead
increas wild-typ ra signal xu
colleagu recent publish data show
cell also produc new respons
newli
gener maintain activ state
latter
rtk aurora kinas signal
appear enhanc ra interact craf
state inhibit
ra inhibitor
revolut approach target activ steric occlud
interact ra raf
affect presenc egf hgf
compoundprevent ra bind raf
demonstr top left lead reduct
perk level inhibit cellular prolifer
expect due revolut approach
demonstr minim chang cellular prolifer
presenc egf hg wherea mrtx-
show increas
see bottom notabl sinc presenc
egf hgf simul paradox reactiv
mapk pathway due loss neg feedback loop
preclin evid indic signific tumor regress nsclc pdac
notabl given respect concentr combin
inhibitor regard vitro
prolifer inhibit cell
confluenc reach day vs
confluenc day respect
appear potent
monotherapi vitro cellular prolifer
kra inhibitor appear
pronounc respect concentr
point
predecessor compound well
increas efficaci trametinib
mek inhibitor ad kra inhibitor
compar kra inhibitor
highlight notion vertic inhibit provid
increment efficaci benefit
addit revolut inhibitor also provid
increment benefit kra inhibitor
one might initi view kra
inhibitor monotherapi efficaci figur
unfavor vs data slide note
differ dose schedul qw
biw vs qd predecessor
like impact efficaci
believ key take-away figur
addit cobimetinib
kra
select mapk-target agent combo investig ras-mut tumor
public firm mention left compris follow rate bayer bayri rate beigen
bgne rate bridgebio buy springwork buy rate johnson
johnson rate rate merck co rate
select mapk-target agent combo investig
public firm mention compris follow novarti ag nv rate redx pharma redx rate revolut
medicin rate sanofi sni rate
trametinibpan-raf ribociclibpan-raf inhibitorkra kra revolut medicin inc
ra inhibitor program includ use
nsclc
forecast market entri occur
respect potenti entri occur
one year approv
forecast peak penetr rate front-
line set second-lin set
estim probabl approv believ
ra inhibitor could initi price per
month believ justifi potenti best-in-
revolut inhibitor round
pipelin present upsid valuat
modifi
appear overlap specif kra mutat
sensit inhibit
preclin data boehring
clinic candid bi tool compound bi
present takeaway includ
cell harbor appear
sensit inhibit rel similar inhibit
across varieti preclin model harbor differ
kra mutant combin inhibitor /- trametinib
mek inhibitor demonstr anti-tumor activitytumor stasi
regressionrel either agent alon see next page
anti-tumor activ across varieti cell line
appear activ
mutat hr breast cancer
gbm model loss
rapamycin associ
signific toxic wait
toxic data consid includ
model therefor view
driver potenti upsid
major pharma appetit precis oncolog asset
appet target given
multitud mapk pathway-target
asset rapid rout market
forefront within
competit landscap moreov
clear histori major pharma firm
acquir biotech firm select
public compani mention compris follow rate rate
astella alpmf rate astrazeneca plc azn rate co rate glaxosmithklin gsk
rate merck rate rate roch rog sw rate co ltd
tkphf rate
potenti premium price one reason
major pharma interest precis oncolog
drugcompanytargetsmonthli wac recommend doseyearli alecensa alectinib roch rhbbi alunbrig brigatinib takeda tak cabometyx cabozantinib rate vegfr caprelsa vandetanib sanofi sni rate egfr gilotrif afatinib boehring iressa gefitinib astrazeneca azn lorbrena larotinib rate rozlytrek entrectinib roch rhbbi tagrisso osimertinib astrazeneca azn tarceva erlotinib roch rhbbi vitrakvi larotrectinib bayer bayri vizimpro dacomitinib xalkori crizotinib rate zykadia ceritinib novarti nv rate yearli cost monthli wac month gener avail revolut medicin inc
global revenu yoy nsclc tagrisso nsclc tagrisso- tagrisso tagrisso mek nsclc mek mek mek chemo nsclc chemo- chemo chemo kra yoy nsclc- nsclc- nsclc nsclc nsclc- nsclc nsclc total revenu revolution- inc
util probabl approv combo tagrisso kra inhibitor due view sound mechanist
rational encourag preclin data demonstr monotherapi efficaci also use probabl approv combin
plu mek inhibitor mab given potenti safeti issu combin mek inhibitor due novel natur
combin
util probabl approv revolut ra inhibitor nsclc due encourag preclin data
monotherapi respons rate potenti inferior kra inhibitor
discount cash flow dcf assess
appli valu
discount ratetyp assign
termin growth rate deriv
termin valu given number
pipelin program termin growth
rate appear reason view
base
corpor tax rate
busi
occup tax california
support conclus
could worth roughli
time frame given fact
share trade
mm except amount per share phase lof braf class begin nsclcra valu firm debt valu firm per shareproduct launch yearpeak sale yearpeak salesroyalti rate us eu probabl launch inc
sum present valu
period cash flow
growth rateperpetu growth growth factor termin valueperiod assumptionsdiscount year capit work capit depreci net debt-fre factor net debt-fre revolut medicin inc
review outlook
forecast revenu
believ revolut may start gener revenu
lead asset begin turn cash flow-posit
model gross margin consid attain given
fact revolut asset small molecul
anticip increas oper expens revolut
medicin enrol continu initi clinic develop
advanc addit preclin candid thu project total
oper expens million million
respect forecast spend sale
commensur self-commerci note possibl
revolut medicin could acquir base promis
compani roughli million share common stock
outstand option purchas million share
restrict stock unit warrant outstand
revolut million cash cash equival
believ suffici fund oper activ well
project futur revenu could tax rate
net oper loss carryforward nol deplet base
 feder corpor tax rate corpor tax
rate california revolut nol feder
california massachusett new jersey incom tax purpos
million million million million
respect feder massachusett nol expir start
except million feder nol carri
forward indefinit california nol shall expir start
new jersey nol shall expir start
forecast dilut net loss per share
project revolut may becom profit
forecast depend receipt fda approv
ra inhibitor
revolut medicin never profit compani
guarante ever becom profit
even lead candid approv may
need rais capit futur order fund oper
regulatori process involv submiss
larg amount
clinic preclin data guarante data
set even
fda approv
applic approv
eu may requir addit studi
includ increas number european patient
furnish would suffici
guarante
ra
inhibitor sale effort success
absolut certainti anoth agent current develop might
prefer physician futur detriment
ra inhibitor sale may lead
profit may differ materi project gener
consensu may implic price stock
revolut medicin may need seiz market share
substanti larger entrench compani might prove
challeng sever target market revolut medicin
pursu may prove difficult inde imposs penetr
effect without substanti sale market infrastructur
could prove unfeas revolut medicinesa small
companyto establish maintain
revolut medicin primarili develop precis oncolog
medicin target oncogene-driven cancer although find
preclin data encourag
consid guarante futur clinic commerci success
context preclin natur data current competit
landscap includ multipl compani substanti
greater resourc
drug price environ subject constant chang
current basi controversi drug price legisl
could enforc price limit certain drug includ
otherwis might expect benefit premium price
expect debat drug price subsid near-term
 countri reimburs subject tighter control due
budgetari
concern single-pay healthcar system
accordingli achiev reason price may possibl ex-u
revolut medicin file patent may protect
ra inhibitor respect
guarante
challeng addit enforc claim may difficult
countri patent law may less stringent
patent upheld court
biotech industri inher volatil subject govern
regul past target legisl new sector-specif
